Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Ascenta Therapeutics"
Count: 12
Selected: 0
| NCT ID | Title |
|---|
| NCT01265199 | Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) | ||
| NCT00561197 | An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer | ||
| NCT00286793 | Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC | ||
| NCT00275431 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | ||
| NCT00571675 | A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) | ||
| NCT00544960 | A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer | ||
| NCT00440388 | Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma | ||
| NCT00397293 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | ||
| NCT00286806 | A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer | ||
| NCT00286780 | Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia | ||
| NCT00988169 | Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | ||
| NCT00934076 | Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer |
